Industry
TR Therapeutics
Total Trials
5
Recruiting
2
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed trials have results
Key Signals
2 recruiting2 with results
Enrollment Performance
Analytics
Phase 2
2(40.0%)
Phase 3
2(40.0%)
Phase 1
1(20.0%)
5Total
Phase 2(2)
Phase 3(2)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT06707090Phase 3Recruiting
Tissue Repair Gel in Venous Leg Ulcers (US)
Role: lead
NCT06707103Phase 3Recruiting
Tissue Repair Gel in Venous Leg Ulcers in AU/US
Role: lead
NCT00792688Phase 2Completed
Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation
Role: lead
NCT00656474Phase 1Completed
Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation
Role: lead
NCT03154619Phase 2Active Not Recruiting
Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers
Role: collaborator
All 5 trials loaded